FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Razelle Kurzrock

Research Profile

Chemicals & Drugs

Disorders

Concepts & Ideas

Co-author Network

Publications

TOP 3
David S Hong; Eucharia C Iwuanyanwu; Gerald S Falchook; Goldy C George; Xiudong Lei; Reena H Mistry; Sarina A Piha-Paul; Bahareh Tavana; Jennifer J Wheler; Razelle Kurzrock
Factors related to biopsy willingness in patients with advanced cancer in a phase 1 clinic for molecularly targeted therapy.
David S Hong; Joann Aaron; Udai Banerji; Goldy C George; Bahareh Tavana; Razelle Kurzrock
Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions.
Leonard A Zwelling; Philip R Cohen; Razelle Kurzrock; Bernard Levin; Lawrence Charles Parish
The karabus affair speaks to larger issues for american academic and medical centers.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Razelle Kurzrock (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: David S Hong; Eucharia C Iwuanyanwu; Gerald S Falchook; Goldy C George; Xiudong Lei; Reena H Mistry; Sarina A Piha-Paul; Bahareh Tavana; Jennifer J Wheler; Razelle Kurzrock
Factors related to biopsy willingness in patients with advanced cancer in a phase 1 clinic for molecularly targeted therapy.
Journal of cancer research and clinical oncology 2013;139(6):963-70.
2013: David S Hong; Joann Aaron; Udai Banerji; Goldy C George; Bahareh Tavana; Razelle Kurzrock
Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions.
Cancer treatment reviews 2013;39(4):375-87.
2013: Leonard A Zwelling; Philip R Cohen; Razelle Kurzrock; Bernard Levin; Lawrence Charles Parish
The karabus affair speaks to larger issues for american academic and medical centers.
Clinics in dermatology 2013;31(3):325-6.
2013: Aung Naing; Razelle Kurzrock
Dodging a dogma: is treating beyond progression beneficial?
Cancer chemotherapy and pharmacology 2013;71(5):1385-6.
2013: Roger B Cohen; Darron Green; Steinar Aamdal; Maria Cavallin; Maria Learoyd; Marta Nyakas; Ian Smith; Razelle Kurzrock
A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies.
European journal of cancer (Oxford, England : 1990) 2013;49(7):1521-9.
2013: Floyd Christopher Holsinger; David S Hong; Filip Janku; Sarina Anne Piha-Paul; Apostolia-Maria Tsimberidou; Johnique T Atkins; Razelle Kurzrock
Biomarker-directed therapy of squamous carcinomas of the head and neck: targeting PI3K/PTEN/mTOR pathway.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(9):e137-40.
2013: Aung Naing; Alexandria Phan; Patricia M LoRusso; H X Chen; L A Doyle; S Fu; Mouhammed Amir Habra; D Hong; Razelle Kurzrock
Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma.
British journal of cancer 2013;108(4):826-30.
2013: Gerald S Falchook; David S Hong; Sharon Hymes; Harrison P Nguyen; Victor G Prieto; Peter Rady; Stephen K Tyring; Razelle Kurzrock
Merkel Cell Polyomavirus and HPV-17 Associated With Cutaneous Squamous Cell Carcinoma Arising in a Patient With Melanoma Treated With the BRAF Inhibitor Dabrafenib.
JAMA dermatology (Chicago, Ill.) 2013;149(3):322-6.
2013: Filip Janku; Laura S Angelo; Helen J Huang; Razelle Kurzrock
A kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R) : implications for inhibition of the IGF-1R signal.
Oncotarget 2013;4(3):463-73.
2013: Laura S Angelo; William G Bornmann; David H Hawke; David S Maxwell; Ian E McCutcheon; Zhenghong Peng; John M Slopis; Duoli Sun; Ji Yuan Wu; Razelle Kurzrock
Binding partners for curcumin in human schwannoma cells: biologic implications.
Bioorganic & medicinal chemistry 2013;21(4):932-9.
2013: Javier Munoz; Razelle Kurzrock
Unilateral proptosis.
JAMA : the journal of the American Medical Association 2013;309(6):605-6.
2013: G S Falchook; M C Heinrich; C C Bastida; C Beadling; S C Blackman; J Patterson; J C Trent; Razelle Kurzrock
BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance.
Oncotarget 2013;4(2):310-5.
2013: Chaan S Ng; Wei Wei; Ella F Anderson; Adam G Chandler; Delise H Herron; Razelle Kurzrock; Chusilp Charnsangavej
Effect of sampling frequency on perfusion values in perfusion CT of lung tumors.
AJR. American journal of roentgenology 2013;200(2):W155-62.
2013: Gerald S Falchook; Filip Janku; David J Stewart; Anne S Tsao; Christel C Bastida; Razelle Kurzrock
Non-small-cell lung cancer with HER2 exon 20 mutation: regression with dual HER2 inhibition and anti-VEGF combination treatment.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2013;8(2):e19-20.
2013: Apostolia M Tsimberidou; Jennifer Wheler; Rony Avritscher; Gerald S Falchook; Adoneca Fortier; Siqing Fu; David Hong; Mark B Leick; Joann Lim; Aung Naing; Sarina A Piha-Paul; Ishwaria M Subbiah; Razelle Kurzrock
Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver.
Cancer chemotherapy and pharmacology 2013;71(2):389-97.
2013: Rajul K Jain; David Hong; J Jack Lee; Razelle Kurzrock
Reply to A. Levy et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):396.
2013: David J Stewart; Razelle Kurzrock
Fool's gold, lost treasures, and the randomized clinical trial.
BMC cancer 2013;13():193.
2013: Razelle Kurzrock; David J Stewart
Compliance in early-phase cancer clinical trials research.
The oncologist 2013;18(3):308-13.
2013: Gerald S Falchook; Siqing Fu; David S Hong; Yunfang Jiang; Sonia K Morgan-Linnell; Aung Naing; Sarina A Piha-Paul; Apostolia M Tsimberidou; Jennifer J Wheler; Ralph G Zinner; Christel Bastida; Razelle Kurzrock
Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer.
Oncotarget 2013;4(1):118-27.
2013: Ishwaria M Subbiah; Vivek Subbiah; Apostolia M Tsimberidou; Jennifer J Wheler; Robert A Wolff; Aung Naing; Sarina Piha-Paul; Gerald S Falchook; Siqing Fu; Kenneth R Hess; David S Hong; Filip Janku; Milind Javle; Ahmed O Kaseb; Razelle Kurzrock
Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials.
Oncotarget 2013;4(1):156-65.
2013: Filip Janku; Javier Munoz; Vivek Subbiah; Razelle Kurzrock
A tale of two histiocytic disorders.
The oncologist 2013;18(1):2-4.
2013: Philip R Cohen; Razelle Kurzrock; Lawrence Charles Parish
Warning signal: unaware of an in absentia conviction, South African cancer specialist jailed on return to the United Arab Emirates.
Clinics in dermatology 2013;31(1):128-30.
2013: Filip Janku; Gerald S Falchook; Siqing Fu; David S Hong; J Jack Lee; Rajyalakshmi Luthra; Aung Naing; Sarina A Piha-Paul; Vanda M Stepanek; Apostolia M Tsimberidou; Jennifer J Wheler; Razelle Kurzrock
PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.
Cancer research 2013;73(1):276-84.
2012: Razelle Kurzrock; François Lokiec; Sridhar Mani; Sonia K Morgan-Linnell; Aby Buchbinder; Imran Chaudhary; Siqing Fu; Mohammed H Ghalib; Sanjay Goel; David Hong; Keyvan Rezai; Saik Urien; Jennifer Wheler; Mary Mulcahy
Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies.
Cancer 2012;118(24):6144-51.
2012: Filip Janku; Gerald S Falchook; Siqing Fu; Ignacio Garrido-Laguna; David S Hong; Jack J Lee; Rajyalakshmi Luthra; Stacy L Moulder; Aung Naing; Sarina A Piha-Paul; Vanda M Stepanek; Apostolia M Tsimberidou; Jennifer J Wheler; Razelle Kurzrock
PIK3CA mutations in advanced cancers: characteristics and outcomes.
Oncotarget 2012;3(12):1566-75.
2012: Jason R Westin; Razelle Kurzrock
It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy.
Molecular cancer therapeutics 2012;11(12):2549-55.
2012: David S Hong; Scott Kopetz; Gerald Falchook; Siqing Fu; Ignacio Garrido-Laguna; Aung Naing; Jesal C Patel; Apostolia M Tsimberidou; Jennifer Wheler; Sijin Win; Razelle Kurzrock
Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience.
Clinical colorectal cancer 2012;11(4):297-303.
2012: Filip Janku; Donald A Berry; Jing Gong; Henrique A Parsons; David J Stewart; Razelle Kurzrock
Outcomes of phase II clinical trials with single-agent therapies in advanced/metastatic non-small cell lung cancer published between 2000 and 2009.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(22):6356-63.
2012: Apostolia-Maria Tsimberidou; Sijin Wen; Jennifer J Wheler; Yang Ye; Donald Berry; Gerald S Falchook; Siqing Fu; David S Hong; Nancy G Iskander; Filip Janku; Rajyalakshmi Luthra; Aung Naing; Sarina Piha-Paul; Razelle Kurzrock
Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(22):6373-83.
2012: Javier Munoz; Razelle Kurzrock
Targeted therapy in rare cancers--adopting the orphans.
Nature reviews. Clinical oncology 2012;9(11):631-42.
2012: Vivek Subbiah; Jonathan Trent; Avi Ashkenazi; Robert E Brown; Jamie Buryanek; Roy Herbst; Razelle Kurzrock
Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist.
Molecular cancer therapeutics 2012;11(11):2541-6.
2012: Zheng D Liang; Yan Long; Gordon B Mills; Niramol Savaraj; Wen-Bin Tsai; Fan Zhang; Helen H W Chen; Siqing Fu; Mihai Gagea-Iurascu; Bryan T Hennessy; Razelle Kurzrock; M Tien Kuo
Mechanistic basis for overcoming platinum resistance using copper chelating agents.
Molecular cancer therapeutics 2012;11(11):2483-94.
2012: John Moroney; Stacy Moulder; Aung Naing; Jennifer Wheler; Gerald Falchook; Siqing Fu; Thorunn Helgason; David Hong; Charles Levenback; Razelle Kurzrock
Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(20):5796-805.
2012: Philip R Cohen; Sarina A Piha-Paul; Victor G Prieto; Razelle Kurzrock
The "shield sign" in two men with metastatic salivary duct carcinoma to the skin: cutaneous metastases presenting as carcinoma hemorrhagiectoides.
The Journal of clinical and aesthetic dermatology 2012;5(9):27-36.
2012: Siqing Fu; David Hong; Adrienne Howard; Aung Naing; Sarina Piha-Paul; Apostolia Tsimberidou; Jennifer Wheler; Fedricker Diane Barber; Gerald Falchook; Razelle Kurzrock
Advance care planning in patients with cancer referred to a phase I clinical trials program: the MD Anderson Cancer Center experience.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(23):2891-6.
2012: Gerald S Falchook; Johanna C Bendell; Howard A Burris; Douglas J DeMarini; Keith Flaherty; Rene Gonzalez; Michael S Gordon; Jeffrey R Infante; Kevin B Kim; Razelle Kurzrock; Ngocdiep T Le; Peter F Lebowitz; Karl D Lewis; Wells A Messersmith; Christopher Moy; Peter J O'Dwyer; Vijay G R Peddareddigari; Lori T Roadcap; Peng Sun; Stephen A Szabo; Nicholas J Vogelzang; Leslie A Fecher
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.
The lancet oncology 2012;13(8):782-9.
2012: Jeffrey R Infante; Razelle Kurzrock; Ngocdiep T Le; Shannon R Morris; Sujatha Nallapareddy; Vijay G R Peddareddigari; Yanmei Xu; Carlos Becerra; Johanna C Bendell; Howard A Burris; Donna S Cox; Douglas J DeMarini; Gail Eckhardt; Gerald S Falchook; Leslie A Fecher; Keith Flaherty; Michael S Gordon; Lowell Hart; Wells A Messersmith
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
The lancet oncology 2012;13(8):773-81.
2012: David S Hong; Daniel W Bowles; S Gail Eckhardt; Gerald S Falchook; Goldy C George; Diana F Hausman; Roy S Herbst; Kevin Klucher; Razelle Kurzrock; Wells A Messersmith; Cindy L O'Bryant; Scott Peterson; Alex C H Vo; Antonio Jimeno
A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(15):4173-82.
2012: Rajul K Jain; Jing Gong; David Hong; J Jack Lee; Aung Naing; Chaan Ng; Jennifer Wheler; Razelle Kurzrock
Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(21):2684-90.
2012: Chaan S Ng; Wei Wei; Ella F Anderson; Adam G Chandler; Delise H Herron; Razelle Kurzrock; Chusilp Charnsangavej
Effect of dual vascular input functions on CT perfusion parameter values and reproducibility in liver tumors and normal liver.
Journal of computer assisted tomography 2012;36(4):388-93.
2012: Anthony W Tolcher; Ka Wang; Zhi-Xin Xu; John F Boylan; Arvind Dasari; Mark DeMario; Jonathan Deutsch; Gerald S Falchook; Darlene G Gibbon; Astrid Koehler; Razelle Kurzrock; Eunice L Kwak; Wells A Messersmith; Steven A Middleton; Stanislaw M Mikulski; Kyriakos P Papadopoulos; Amita Patnaik; Geoffrey I Shapiro; James Song; Jennifer J Wheler
Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(19):2348-53.
2012: Siqing Fu; David M Gershenson; Bryan T Hennessy; Adrienne Howard; Ed Jackson; Zhenlin Ju; John J Kavanagh; Vikas Kundra; Razelle Kurzrock; Charles F Levenback; Jane Li; Yang Li; Maurie Markman; Edward Atkinson; Robert C Bast; Robert L Coleman; Kevin R Coombes; Kristine Dice; Mary Dyer; Chaan S Ng; Anil K Sood; Katherine Stemke-Hale; Judith K Wolf; Gordon B Mills
Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.
Gynecologic oncology 2012;126(1):47-53.
2012: David S Hong; Sergej Konoplev; Marina Konopleva; Donald Kufe; Razelle Kurzrock; Donald Lawrence; Hillard Lazarus; Colin J Meyer; James Mier; Aung Naing; Geoffrey I Shapiro; Jeffrey G Supko; Jennifer Wheler; Michael Andreeff; Joseph Paul Eder; Deborah A Ferguson; Xiaoying He; Bruce J Dezube
A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(12):3396-406.
2012: Vivek Subbiah; Razelle Kurzrock
Ewing's sarcoma: overcoming the therapeutic plateau.
Discovery medicine 2012;13(73):405-15.
2012: Laura J Paul; Philip R Cohen; Razelle Kurzrock
Eyelash trichomegaly: review of congenital, acquired, and drug-associated etiologies for elongation of the eyelashes.
International journal of dermatology 2012;51(6):631-46; quiz 643-4, 646.
2012: Apostolia M Tsimberidou; Sijin Wen; Joann Lim; Aung Naing; Ishwaria M Subbiah; Adoneca H Fortier; Siqing Fu; David S Hong; Razelle Kurzrock
Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis.
Hepato-gastroenterology 2012;59(116):960-4.
2012: Javier Munoz; Aung Naing; Ming Qi; Razelle Kurzrock
Cutaneous Castleman disease.
British journal of haematology 2012;157(6):652.
2012: Siqing Fu; Macus Tien Kuo; Caroline Fu; Aung Naing; Razelle Kurzrock
Overcoming platinum resistance through the use of a copper-lowering agent.
Molecular cancer therapeutics 2012;11(6):1221-5.
2012: Gerald S Falchook; Omid Hamid; Jeffrey R Infante; Tobias H Arkenau; Samuel C Blackman; Michael P Brown; C Martin Curtis; Kevin B Kim; Razelle Kurzrock; Peter Lebowitz; Georgina V Long; Bo Ma; Michael Millward; Steven J O'Day; Daniele Ouellet; Anna C Pavlick; Richard F Kefford
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.
Lancet 2012;379(9829):1893-901.
2012: Jennifer Wheler; Gerald Falchook; Siqing Fu; David Hong; Stacy Moulder; Aung Naing; Sarina Piha-Paul; Bettzy Stephen; Apostolia-Maria Tsimberidou; Sijin Wen; Razelle Kurzrock
Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(10):2922-9.
2012: Aung Naing; Patricia M LoRusso; Joseph Ludwig; Pete Anderson; Robert S Benjamin; Helen X Chen; Laurence A Doyle; Siqing Fu; David S Hong; Razelle Kurzrock
Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(9):2625-31.
2012: G S Falchook; David S Hong; J Lim; Aung Naing; J Wheler; M Duvic; Razelle Kurzrock
Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies.
Cancer chemotherapy and pharmacology 2012;69(5):1117-26.
2012: David S Hong; Sam Blackman; Gerald Falchook; Vicki Goodman; Razelle Kurzrock; Jeffery J Legos; Chengwen Liu; Gregory Lizee; Laszlo G Radvanyi; Antonio Scarmadio; Luis Vence; Patrick Hwu
BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(8):2326-35.
2012: Filip Janku; Gerald S Falchook; Siqing Fu; Ignacio Garrido-Laguna; David S Hong; J Jack Lee; Karen H Lu; Rajyalakshmi Luthra; Stacy L Moulder; Aung Naing; Apostolia-Maria Tsimberidou; Shannon N Westin; Jennifer J Wheler; Razelle Kurzrock
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(8):777-82.
2012: Ignacio Garrido-Laguna; David S Hong; Filip Janku; Aung Naing; Apostolia M Tsimberidou; Christos Vaklavas; Sijin Wen; Gerald S Falchook; Siqing Fu; Razelle Kurzrock
Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center.
Cancer 2012;118(5):1422-8.
2012: Vivek Subbiah; Ian E McCutcheon; John M Slopis; Jackson Hamilton; David S Hong; Leena M Ketonen; Razelle Kurzrock
Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(5):e64-8.
2012: Razelle Kurzrock; Alain Mita; Stacy Moulder; Kamalesh Sankhala; Danielle Bouchard; Andrew Brenner; Chandtip Chandhasin; Kelly Elian; Nash Gabrail; Carrie Smith; John Sarantopoulos
Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors.
Molecular cancer therapeutics 2012;11(2):308-16.
2012: Ignacio Garrido-Laguna; David S Hong; Filip Janku; Rajyalakshmi Luthra; Aung Naing; Ly M Nguyen; Xuemei Wang; Jenifer J Wheler; Gerald S Falchook; Siqing Fu; Razelle Kurzrock
KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors.
PloS one 2012;7(5):e38033.
2012: Henrique A Parsons; Michael Pontikos; Apostolia M Tsimberidou; Sijin Wen; Vickie E Baracos; Siqing Fu; David Hong; Razelle Kurzrock
Evaluation of the clinical relevance of body composition parameters in patients with cancer metastatic to the liver treated with hepatic arterial infusion chemotherapy.
Nutrition and cancer 2012;64(2):206-17.
2012: Javier Munoz; David Hong; Razelle Kurzrock
Anticoagulation-induced severe bleeding in a patient receiving bevacizumab therapy.
International journal of hematology 2012;95(1):1-2.
2011: Apostolia-Maria Tsimberidou; Cynthia Uehara; Patrick Urban; Suraj Anand; Howard Burris; Nancy Lewis; Tony Reid; Eugene Y Tan; Razelle Kurzrock
Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer.
Cancer chemotherapy and pharmacology 2011;68(6):1507-16.
2011: Aung Naing; Saneese K Stephen; Jennifer J Wheler; Xiudong Lei; Chandtip Chandhasin; Gerald Falchook; Moshe Frenkel; Siqing Fu; David S Hong; Razelle Kurzrock
Prevalence of complementary medicine use in a phase 1 clinical trials program: the MD Anderson Cancer Center Experience.
Cancer 2011;117(22):5142-50.
2011: Vivek Subbiah; Laura S Angelo; Razelle Kurzrock
Insulin-like growth factor 1 receptor (IGF-1R) inhibitor: another arrow in the quiver - Will it hit the moving target?
Expert opinion on investigational drugs 2011;20(11):1471-7.
2011: Laura S Angelo; Scott Kopetz; Ian E McCutcheon; Feng Meng; John M Slopis; Michael Sun; Ji Yuan Wu; Razelle Kurzrock
Combining curcumin (diferuloylmethane) and heat shock protein inhibition for neurofibromatosis 2 treatment: analysis of response and resistance pathways.
Molecular cancer therapeutics 2011;10(11):2094-103.
2011: John W Moroney; Stacy Moulder; Aung Naing; Matthew P Schlumbrecht; Diane C Bodurka; Robert L Coleman; Thorunn Helgason; David S Hong; Filip Janku; Razelle Kurzrock
A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(21):6840-6.
2011: David S Hong; Sunil K Kadam; Razelle Kurzrock; Funda Meric-Bernstam; Aung Naing; Aejaz Nasir; Yun Oh; Valérie André; Les Brail; Sophie Callies; Mayer Fishman; Timothy R Holzer; Jennifer Wheler; George Simon
A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(20):6582-91.
2011: Brandi A Barosh; Patricia C Hasen; Cynthia Holmes; Lovely M Keerikattu; Geri LoBiondo-Wood; Mary S Manappurathu; Shobha V Pai; Julie H Segovia; Razelle Kurzrock
Advancing the scope of nursing practice: hepatic arterial catheter removal.
Clinical journal of oncology nursing 2011;15(5):465-8.
2011: Aung Naing; Chaan Ng; Eric Rohren; Angelika Burger; Naifa Busaidy; Chandtip Chandhasin; Helen X Chen; Lawrence A Doyle; Sachin Gupta; Lance K Heilbrun; David Hong; Razelle Kurzrock; Xiudong Lei; Patricia M LoRusso
Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(18):6052-60.
2011: Sarina A Piha-Paul; Philip R Cohen; Razelle Kurzrock
Salivary duct carcinoma: targeting the phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with temsirolimus.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(26):e727-30.
2011: Siqing Fu; David S Hong; Adrienne Howard; Aung Naing; Joseph Nates; Kristen Price; Sijin Wen; Jennifer Wheler; Diane Barber; Gerald Falchook; Razelle Kurzrock
Outcome analyses after the first admission to an intensive care unit in patients with advanced cancer referred to a phase I clinical trials program.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(26):3547-52.
2011: Filip Janku; Lubos B Petruzelka; David J Stewart; Ignacio Garrido-Laguna; Razelle Kurzrock
Novel therapeutic targets in non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011;6(9):1601-12.
2011: Ignacio Garrido-Laguna; Manuel Hidalgo; Razelle Kurzrock
The inverted pyramid of biomarker-driven trials.
Nature reviews. Clinical oncology 2011;8(9):562-6.
2011: Chaan S Ng; Wei Wei; Ella F Anderson; Adam G Chandler; Delise H Herron; Razelle Kurzrock; Chusilp Charnsangavej
Reproducibility of CT perfusion parameters in liver tumors and normal liver.
Radiology 2011;260(3):762-70.
2011: Filip Janku; David S Hong; David J McConkey; Razelle Kurzrock
Autophagy as a target for anticancer therapy.
Nature reviews. Clinical oncology 2011;8(9):528-39.
2011: Chaan S Ng; Wei Wei; Ella F Anderson; Adam G Chandler; Chusilp Charnsangavej; Delise H Herron; Razelle Kurzrock
Reproducibility of perfusion parameters obtained from perfusion CT in lung tumors.
AJR. American journal of roentgenology 2011;197(1):113-21.
2011: Razelle Kurzrock; Ranee Mehra; Thomas Müller; Forlisa Nauling; Chaan S Ng; David G Pfister; Mark J Ratain; Douglas W Ball; Ezra E W Cohen; Roger B Cohen; Arlene A Forastiere; John Frye; Robert F Gagel; David S Hong; Linda Janisch; Steven I Sherman; Lei Ye; Ravi Salgia
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(19):2660-6.
2011: Siqing Fu; David S Hong; Kirk S Culotta; Gerald S Falchook; Timothy L Madden; David C Madoff; Stacy L Moulder; Aung Naing; Chaan S Ng; Razelle Kurzrock
Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel: toxicity, pharmacokinetics, and activity.
Molecular cancer therapeutics 2011;10(7):1300-7.
2011: Vivek Subbiah; Razelle Kurzrock
Phase 1 clinical trials for sarcomas: the cutting edge.
Current opinion in oncology 2011;23(4):352-60.
2011: Stacy Moulder; Jennifer Wheler; John Moroney; Phuong K Morrow; Constance T Albarracin; Daniel Booser; Thorunn Helgason; Kimberly Koenig; Razelle Kurzrock
Responses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(19):e572-5.
2011: Apostolia-Maria Tsimberidou; Cynthia Uehara; Sijin Wen; Jennifer Wheler; Siqing Fu; David Hong; Katherine Letourneau; Stephen E McRae; Aung Naing; Razelle Kurzrock
Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement.
Cancer chemotherapy and pharmacology 2011;68(1):247-53.
2011: Apostolia-Maria Tsimberidou; Cynthia Uehara; Sijin Wen; Jennifer Wheler; David Hong; Nancy G Iskander; Katherine Letourneau; Aung Naing; Razelle Kurzrock
Phase I clinical trial outcomes in 93 patients with brain metastases: the MD anderson cancer center experience.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(12):4110-8.
2011: Sarina A Piha-Paul; David S Hong; Razelle Kurzrock
Response of lymphangioleiomyomatosis to a mammalian target of rapamycin inhibitor (temsirolimus) -based treatment.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(12):e333-5.
2011: Siqing Fu; Wei Hu; Revathy Iyer; John J Kavanagh; Robert L Coleman; Charles F Levenback; Anil K Sood; Judith K Wolf; David M Gershenson; Maurie Markman; Bryan T Hennessy; Razelle Kurzrock; Robert C Bast
Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer.
Cancer 2011;117(8):1661-9.
2011: David S Hong; Maria Cabanillas; Jennifer Wheler; Aung Naing; Apostolia-Maria Tsimberidou; Lei Ye; Steven G Waguespack; Mike Hernandez; Adel K El Naggar; Savita Bidyasar; John Wright; Steven I Sherman; Naifa L Busaidy; Alder K El Naggar; Razelle Kurzrock
Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.
The Journal of clinical endocrinology and metabolism 2011;96(4):997-1005.
2011: Filip Janku; Apostolia-Maria Tsimberidou; Ignacio Garrido-Laguna; Xuemei Wang; Rajyalakshmi Luthra; David S Hong; Aung Naing; Gerald S Falchook; John W Moroney; Sarina A Piha-Paul; Jennifer J Wheler; Stacy L Moulder; Siqing Fu; Razelle Kurzrock
PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.
Molecular cancer therapeutics 2011;10(3):558-65.
2011: Philip R Cohen; Susan M Escudier; Razelle Kurzrock
Cetuximab-associated elongation of the eyelashes: case report and review of eyelash trichomegaly secondary to epidermal growth factor receptor inhibitors.
American journal of clinical dermatology 2011;12(1):63-7.
2011: Hazem El-Osta; Gerald Falchook; David Hong; Filip Janku; Kevin Kim; Aung Naing; Apostolia-Maria Tsimberidou; Sijin Wen; Razelle Kurzrock
BRAF mutations in advanced cancers: clinical characteristics and outcomes.
PloS one 2011;6(10):e25806.
2011: Helen J Huang; Klaus-Peter Kuenkele; Laura S Angelo; Henrique A Parsons; Jordi Rodon; Michael Sun; Jonathan Trent; Razelle Kurzrock
R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis.
PloS one 2011;6(10):e26060.
2011: Hazem El-Osta; Gerald Falchook; Siqing Fu; Marshall Hicks; David Hong; Aung Naing; Apostolia-Maria Tsimberidou; Sijin Wen; Jennifer Wheler; Razelle Kurzrock
Outcomes of research biopsies in phase I clinical trials: the MD anderson cancer center experience.
The oncologist 2011;16(9):1292-8.
2011: Filip Janku; Gerald S Falchook; Siqing Fu; Ignacio Garrido-Laguna; David S Hong; J Jack Lee; Rajyalakshmi Luthra; Aung Naing; Apostolia-Maria Tsimberidou; Razelle Kurzrock
PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.
PloS one 2011;6(7):e22769.
2011: David M Harris; Inbal Hazan-Haley; Vikas Kundra; Razelle Kurzrock; Ping Li; Jie Liu; Zhiming Liu; Murali Ravoori; Sheela Singh; Michael Sun; Lynne Abruzzo; Carlos Bueso-Ramos; Kevin Coombes; Lin Han; Zeev Estrov
Transformation of human mesenchymal cells and skin fibroblasts into hematopoietic cells.
PloS one 2011;6(6):e21250.
2011: Vivek Subbiah; Aung Naing; Robert E Brown; Helen Chen; Laurence Doyle; Patricia M LoRusso; Robert Benjamin; Pete Anderson; Razelle Kurzrock
Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures.
PloS one 2011;6(4):e18424.
2011: Hazem E El-Osta; Razelle Kurzrock
Castleman's disease: from basic mechanisms to molecular therapeutics.
The oncologist 2011;16(4):497-511.
2011: Filip Janku; Apostolia-Maria Tsimberidou; Xuemei Wang; David S Hong; Aung Naing; Jing Gong; Ignacio Garrido-Laguna; Henrique A Parsons; Ralph G Zinner; Razelle Kurzrock
Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic.
The oncologist 2011;16(3):327-35.
2011: Aung Naing; James M Reuben; Luis H Camacho; Hui Gao; Bang-Ning Lee; Evan N Cohen; Claire Verschraegen; Saneese Stephen; Joann Aaron; David Hong; Jennifer Wheler; Razelle Kurzrock
Phase I Dose Escalation Study of Sodium Stibogluconate (SSG), a Protein Tyrosine Phosphatase Inhibitor, Combined with Interferon Alpha for Patients with Solid Tumors.
Journal of Cancer 2011;2():81-9.
2011: Apostolia-Maria Tsimberidou; Chris H M Takimoto; Stacy Moulder; Cynthia Uehara; Monica Mita; Catalin Mita; Patrick Urban; Eugene Tan; Yanfeng Wang; David Vining; Razelle Kurzrock
Effects of patupilone on the pharmacokinetics and pharmacodynamics of warfarin in patients with advanced malignancies: a phase I clinical trial.
Molecular cancer therapeutics 2011;10(1):209-17.
2011: Christos Vaklavas; Apostolia-Maria Tsimberidou; Sijin Wen; David Hong; Jennifer Wheler; Chaan S Ng; Aung Naing; Cynthia Uehara; Robert A Wolff; Razelle Kurzrock
Phase 1 clinical trials in 83 patients with pancreatic cancer: The M. D. Anderson Cancer Center experience.
Cancer 2011;117(1):77-85.
2010: Luis H Camacho; Sheila Garcia; Amar M Panchal; JoAnn Lim; David S Hong; Chaan Ng; David C Madoff; Siqing Fu; Isis Gayed; Razelle Kurzrock
Exploratory study of hepatic arterial infusion oxaliplatin with systemic 5-fluorouracil/bevacizumab in patients with refractory solid tumor and extensive liver metastases.
Clinical colorectal cancer 2010;9(5):311-4.
2010: Apostolia-Maria Tsimberidou; Wallace Akerley; Matthias Schabel; David S Hong; Cynthia Uehara; Anil Chhabra; Terri Warren; Gary G Mather; Brent A Evans; Deane P Woodland; Edward A Swabb; Razelle Kurzrock
Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer.
Molecular cancer therapeutics 2010;9(12):3410-9.
2010: Apostolia-Maria Tsimberidou; Chandtip Chandhasin; Razelle Kurzrock
Farnesyltransferase inhibitors: where are we now?
Expert opinion on investigational drugs 2010;19(12):1569-80.
2010: Rakesh K Srivastava; Razelle Kurzrock; Sharmila Shankar
MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo.
Molecular cancer therapeutics 2010;9(12):3254-66.
2010: Roy S Herbst; Razelle Kurzrock; David S Hong; Manuel Valdivieso; Cheng-Pang Hsu; Lovely Goyal; Gloria Juan; Yuying C Hwang; Susan Wong; John S Hill; Greg Friberg; Patricia M LoRusso
A first-in-human study of conatumumab in adult patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(23):5883-91.
2010: Filip Janku; Hesham M Amin; Dan Yang; Ignacio Garrido-Laguna; Jonathan Trent; Razelle Kurzrock
Response of histiocytoses to imatinib mesylate: fire to ashes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(31):e633-6.
2010: Apostolia-Maria Tsimberidou; Stacy Moulder; Siqing Fu; Sijin Wen; Aung Naing; Agop Y Bedikian; Shawn Daring; Cynthia Uehara; Chaan Ng; Michael Wallace; Luis H Camacho; Razelle Kurzrock
Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement.
Cancer chemotherapy and pharmacology 2010;66(6):1087-93.
2010: Siqing Fu; Razelle Kurzrock
Development of curcumin as an epigenetic agent.
Cancer 2010;116(20):4670-6.
2010: Stacy Moulder; Navneet Dhillon; Chaan Ng; David Hong; Jennifer Wheler; Aung Naing; Susan Tse; Amy La Paglia; Robert Dorr; Evan M Hersh; Michelle Boytim; Razelle Kurzrock
A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer.
Investigational new drugs 2010;28(5):634-40.
2010: David Hui; Henrique Parsons; Linh Nguyen; Shana L Palla; Sriram Yennu; Razelle Kurzrock; Eduardo Bruera
Timing of palliative care referral and symptom burden in phase 1 cancer patients: a retrospective cohort study.
Cancer 2010;116(18):4402-9.
2010: Apostolia-Maria Tsimberidou; Siqing Fu; Chaan Ng; Jo Ann Lim; Sijin Wen; David Hong; Jennifer Wheler; Agop Bedikian; Cathy Eng; Michael Wallace; Luis H Camacho; Razelle Kurzrock
A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver.
Cancer 2010;116(17):4086-94.
2010: Vivek Subbiah; Jonathan Trent; Razelle Kurzrock
Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):e415.
2010: Frits van Rhee; Luis Fayad; Peter Voorhees; Richard Furman; Sagar Lonial; Hossein Borghaei; Lubomir Sokol; Julie Crawford; Mark Cornfeld; Ming Qi; Xiang Qin; Jennifer Herring; Corey Casper; Razelle Kurzrock
Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(23):3701-8.
2010: Ignacio Garrido-Laguna; Filip Janku; Gerald S Falchook; Siqing Fu; David S Hong; Aung Naing; Joanne Aaron; Xuemei Wang; Merrill Kies; Razelle Kurzrock
Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(15):4031-7.
2010: Lakshmi Chintala; Razelle Kurzrock
Epidermal growth factor receptor mutation and diverse tumors: case report and concise literature review.
Molecular oncology 2010;4(4):306-8.
2010: Filip Janku; David J Stewart; Razelle Kurzrock
Targeted therapy in non-small-cell lung cancer--is it becoming a reality?
Nature reviews. Clinical oncology 2010;7(7):401-14.
2010: Roy S Herbst; S Gail Eckhardt; Razelle Kurzrock; Scot W Ebbinghaus; Peter J O'Dwyer; Michael S Gordon; William Novotny; Meredith A Goldwasser; Tanyifor M Tohnya; Bert L Lum; Avi Ashkenazi; Adrian M Jubb; David S Mendelson
Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(17):2839-46.
2010: David J Stewart; Simon N Whitney; Razelle Kurzrock
Equipoise lost: ethics, costs, and the regulation of cancer clinical research.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(17):2925-35.
2010: Ernesto Bustinza-Linares; Razelle Kurzrock; Apostolia-Maria Tsimberidou
Salirasib in the treatment of pancreatic cancer.
Future oncology (London, England) 2010;6(6):885-91.
2010: Hazem El-Osta; Filip Janku; Razelle Kurzrock
Successful treatment of Castleman's disease with interleukin-1 receptor antagonist (Anakinra).
Molecular cancer therapeutics 2010;9(6):1485-8.
2010: John W Moroney; Jennifer Wheler; David Hong; Aung Naing; Gerald Falchook; Diane C Bodurka; Robert Coleman; Karen Lu; Lianchun Xiao; Razelle Kurzrock
Phase I clinical trials in 85 patients with gynecologic cancer: the M. D. Anderson Cancer Center experience.
Gynecologic oncology 2010;117(3):467-72.
2010: Razelle Kurzrock; Amita Patnaik; Joseph Aisner; Terri Warren; Stephen Leong; Robert Benjamin; S Gail Eckhardt; Joseph E Eid; Gerard Greig; Kai Habben; Cinara D McCarthy; Lia Gore
A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(8):2458-65.
2010: Aung Naing; Razelle Kurzrock
Chemotherapy resistance and retreatment: a dogma revisited.
Clinical colorectal cancer 2010;9(2):E1-4.
2010: Claire M Mach; Jing Hong Chen; Scott A Mosley; Razelle Kurzrock; Judith A Smith
Evaluation of liposomal curcumin cytochrome p450 metabolism.
Anticancer research 2010;30(3):811-4.
2010: Rajul K Jain; J Jack Lee; David Hong; Maurie Markman; Jing Gong; Aung Naing; Jennifer Wheler; Razelle Kurzrock
Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(4):1289-97.
2010: D Ross Camidge; Roy S Herbst; Michael S Gordon; S Gail Eckhardt; Razelle Kurzrock; Blythe Durbin; Josephine Ing; Tanyifor M Tohnya; Jason Sager; Avi Ashkenazi; Gordon Bray; David Mendelson
A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(4):1256-63.
2010: Jennifer Wheler; Apostolia-Maria Tsimberidou; Stacy Moulder; Massimo Cristofanilli; David Hong; Aung Naing; Raminder Pathak; Suyu Liu; Lei Feng; Razelle Kurzrock
Clinical outcomes of patients with breast cancer in a phase I clinic: the M. D. Anderson cancer center experience.
Clinical breast cancer 2010;10(1):46-51.
2010: Chaan S Ng; David L Raunig; Edward F Jackson; Edward A Ashton; Frederick Kelcz; Kevin B Kim; Razelle Kurzrock; Teresa M McShane
Reproducibility of perfusion parameters in dynamic contrast-enhanced MRI of lung and liver tumors: effect on estimates of patient sample size in clinical trials and on individual patient responses.
AJR. American journal of roentgenology 2010;194(2):W134-40.
2010: Filip Janku; Razelle Kurzrock
Adjuvant interferon in high-risk melanoma: end of the era?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(2):e15-6; author reply e17-8.
2010: Christos Vaklavas; Daniel J Lenihan; Razelle Kurzrock; Apostolia-Maria Tsimberidou
Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?
The oncologist 2010;15(2):130-41.
2010: Aung Naing; Joann Aaron; Razelle Kurzrock
Juice plus or toxicity plus.
The American journal of medicine 2010;123(1):e1-2.
2010: Jordi Rodon; Jose Perez; Razelle Kurzrock
Combining targeted therapies: practical issues to consider at the bench and bedside.
The oncologist 2010;15(1):37-50.
2010: Apostolia-Maria Tsimberidou; MICHELLE RUDEK-RENAUT; David Hong; Chaan S Ng; Jessica Blair; Howard Goldsweig; Razelle Kurzrock
Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors.
Cancer chemotherapy and pharmacology 2010;65(2):235-41.
2009: Apostolia-Maria Tsimberidou; Fadi Braiteh; David J Stewart; Razelle Kurzrock
Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(36):6243-50.
2009: Rachel Davis; Karan P Singh; Razelle Kurzrock; Sharmila Shankar
Sulforaphane inhibits angiogenesis through activation of FOXO transcription factors.
Oncology reports 2009;22(6):1473-8.
2009: Jing Gong; David J Yang; Saady Kohanim; Laura S Angelo; Razelle Kurzrock
Molecular imaging of gefitinib activity in an epidermal growth factor receptor (EGFR)-bearing xenograft model.
Cancer biology & therapy 2009;8(23):2239-47.
2009: Cielito C Reyes-Gibby; Sanjay Shete; Sriram Yennu; Marsha Frazier; Eduardo Bruera; Razelle Kurzrock; Christopher H Crane; James Abbruzzese; Douglas Evans; Margaret R Spitz
Genetic and nongenetic covariates of pain severity in patients with adenocarcinoma of the pancreas: assessing the influence of cytokine genes.
Journal of pain and symptom management 2009;38(6):894-902.
2009: David S Hong; Said M Sebti; Robert A Newman; Michelle A Blaskovich; Lei Ye; Robert F Gagel; Stacy Moulder; Jennifer J Wheler; Aung Naing; Nizar M Tannir; Chaan S Ng; Steven I Sherman; Adel K El-Naggar; Rabia Khan; Jonathan Trent; John J Wright; Razelle Kurzrock
Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(22):7061-8.
2009: Zhiqiang Meng; Peiying Yang; Yehua Shen; Wenying Bei; Ying Zhang; Yongqian Ge; Robert A Newman; Lorenzo Cohen; Luming Liu; Bob Thornton; David Z Chang; Zongxing Liao; Razelle Kurzrock
Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer.
Cancer 2009;115(22):5309-18.
2009: Laura S Angelo; Razelle Kurzrock
Target validation using Phase 0 clinical trials: Promises and pitfalls.
Cancer biology & therapy 2009;8(21):2010-2.
2009: Apostolia-Maria Tsimberidou; Christos Vaklavas; Sijin Wen; David Hong; Jennifer Wheler; Chaan Ng; Aung Naing; Susan Tse; Naifa L Busaidy; Maurie Markman; Steven I Sherman; Razelle Kurzrock
Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience.
The Journal of clinical endocrinology and metabolism 2009;94(11):4423-32.
2009: Razelle Kurzrock; Susan R Pilat; Marcel Bartolazzi; Dwana Sanders; Jill van Wart Hood; SD Tucker; Kevin Webster; Michael A Mallamaci; Steven Strand; Eileen Babcock; Robert C Bast
Project Zero Delay: a process for accelerating the activation of cancer clinical trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(26):4433-40.
2009: D Gareth Evans; Michel Kalamarides; Kim Hunter-Schaedle; Jaishri Blakeley; Jeffrey Allen; Dusica Babovic-Vuskanovic; Allan J Belzberg; Gideon Bollag; Ruihong Chen; Emmanuelle DiTomaso; John Golfinos; Gordon Harris; Abraham Jacob; Ganjam V Kalpana; Matthias Karajannis; Bruce Korf; Razelle Kurzrock; Meng Law; Andrea I McClatchey; Roger Packer; Pamela Roehm; Allan Rubenstein; William Slattery; James H Tonsgard; D Bradley Welling; BRIGITTE WIDEMANN; Kaleb Yohay; Marco Giovannini
Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(16):5032-9.
2009: Roy S Herbst; David Hong; Linnea Chap; Razelle Kurzrock; Edward Jackson; Jeffrey M Silverman; Erik Rasmussen; Yu-Nien Sun; Don Zhong; Yuying C Hwang; Jeffrey L Evelhoch; Jonathan D Oliner; Ngocdiep Le; Lee S Rosen
Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(21):3557-65.
2009: Apostolia-Maria Tsimberidou; Luis H Camacho; Srdan Verstovsek; Chaan Ng; David S Hong; Cynthia K Uehara; Catalina Gutierrez; Shawn Daring; Jan Stevens; Philip B Komarnitsky; Brian Schwartz; Razelle Kurzrock
A phase I clinical trial of darinaparsin in patients with refractory solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(14):4769-76.
2009: Sushma Vemulapalli; Lakshmi Chintala; Apostolia-Maria Tsimberidou; Navjot Dhillon; Xiudong Lei; David Hong; Razelle Kurzrock
Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a Phase I Clinic: the M. D. Anderson Cancer Center experience.
American journal of hematology 2009;84(7):408-13.
2009: Claire M Mach; Lata Mathew; Scott A Mosley; Razelle Kurzrock; Judith A Smith
Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a xenograft human pancreatic cancer model.
Anticancer research 2009;29(6):1895-9.
2009: Sharmila Shankar; Rachel Davis; Karan P Singh; Razelle Kurzrock; Douglas Ross; Rakesh K Srivastava
Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.
Molecular cancer therapeutics 2009;8(6):1596-605.
2009: David J Stewart; Jean-Pierre J Issa; Razelle Kurzrock; Maria I Nunez; Jaroslav Jelinek; David Hong; Yasuhiro Oki; Zhong Guo; Sanjay Gupta; Ignacio I Wistuba
Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(11):3881-8.
2009: Fadi Braiteh; Razelle Kurzrock
Electronic clinical challenges and images in GI. Image 2. Extensive bilateral extracranial subcutaneous fluid collection.
Gastroenterology 2009;136(7):e3-6.
2009: Barbara S Craft; Razelle Kurzrock; Xiudong Lei; Roy Herbst; Scott Lippman; Siqing Fu; Daniel D Karp
The changing face of phase 1 cancer clinical trials: new challenges in study requirements.
Cancer 2009;115(8):1592-7.
2009: Ji Yuan Wu; David J Yang; Laura S Angelo; Sahar Kohanim; Razelle Kurzrock
Molecular imaging of Bcr-Abl phosphokinase in a xenograft model.
Molecular cancer therapeutics 2009;8(3):703-10.
2009: Jennifer Wheler; Apostolia-Maria Tsimberidou; David Hong; Aung Naing; Tiffiny Jackson; Suyu Liu; Lei Feng; Razelle Kurzrock
Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience.
Cancer 2009;115(5):1091-9.
2009: Laura S Angelo; Razelle Kurzrock
Turmeric and green tea: a recipe for the treatment of B-chronic lymphocytic leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(4):1123-5.
2009: Grace Sun; Cindy Berthelot; Yafang Li; Donald A Glass; Dornechia George; Amit Pandya; Razelle Kurzrock; Madeleine Duvic
Poor prognosis in non-Caucasian patients with early-onset mycosis fungoides.
Journal of the American Academy of Dermatology 2009;60(2):231-5.
2009: David J Stewart; Razelle Kurzrock
Cancer: the road to Amiens.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(3):328-33.
2009: Emil J Freireich; Razelle Kurzrock
The role of investigational therapy in management of patients with advanced metastatic malignancy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(2):304-6.
2008: Cielito C Reyes-Gibby; Badi El Osta; Margaret R Spitz; Henrique Parsons; Razelle Kurzrock; Xifeng Wu; Sanjay Shete; Eduardo Bruera
The influence of tumor necrosis factor-alpha -308 G/A and IL-6 -174 G/C on pain and analgesia response in lung cancer patients receiving supportive care.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2008;17(11):3262-7.
2008: Fadi Braiteh; Andres O Soriano; Guillermo Garcia-Manero; David Hong; Marcella M Johnson; Leandro De Padua Silva; Hui Yang; Stefanie Alexander; Johannes Ernst Wolff; Razelle Kurzrock
Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(19):6296-301.
2008: Apostolia-Maria Tsimberidou; Elihu Estey; Sijin Wen; Sherry Pierce; Andrew Lamb; Maher Albitar; Razelle Kurzrock
The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes.
Cancer 2008;113(7):1605-13.
2008: Jordi Rodon; Victoria DeSantos; Robert Jean Ferry; Razelle Kurzrock
Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials.
Molecular cancer therapeutics 2008;7(9):2575-88.
2008: Cielito C Reyes-Gibby; Xifeng Wu; Margaret Spitz; Razelle Kurzrock; Michael Fisch; Eduardo Bruera; Sanjay Shete
Molecular epidemiology, cancer-related symptoms, and cytokines pathway.
The lancet oncology 2008;9(8):777-85.
2008: Navneet Dhillon; Bharat B Aggarwal; Robert A Newman; Robert A Wolff; Ajaikumar Kunnumakkara; James L Abbruzzese; Chaan S Ng; Vladimir Badmaev; Razelle Kurzrock
Phase II trial of curcumin in patients with advanced pancreatic cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(14):4491-9.
2008: Fadi Braiteh; Razelle Kurzrock; Faye M Johnson
Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(20):3460-2.
2008: David S Hong; Srini B Reddy; Victor G Prieto; John J Wright; Nizar M Tannir; Philip R Cohen; A Hafeez Diwan; Harry L Evans; Razelle Kurzrock
Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib.
Archives of dermatology 2008;144(6):779-82.
2008: David Hong; Lei Ye; Robert Gagel; Lakshmi Chintala; Adel K El-Naggar; John Wright; Razelle Kurzrock
Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib.
Molecular cancer therapeutics 2008;7(5):1001-6.
2008: Michael Sun; Zeev Estrov; Yuan Ji; Kevin R Coombes; David H Harris; Razelle Kurzrock
Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells.
Molecular cancer therapeutics 2008;7(3):464-73.
2008: Putao Cen; Madeleine Duvic; Philip R Cohen; Razelle Kurzrock
Increased cancer antigen 27.29 (CA27.29) level in patients with mycosis fungoides.
Journal of the American Academy of Dermatology 2008;58(3):382-6.
2008: Mi-Ae Lyu; Razelle Kurzrock; Michael G Rosenblum
The immunocytokine scFv23/TNF targeting HER-2/neu induces synergistic cytotoxic effects with 5-fluorouracil in TNF-resistant pancreatic cancer cell lines.
Biochemical pharmacology 2008;75(4):836-46.
2008: Razelle Kurzrock; Hagop M Kantarjian; Michelle A Blascovich; Cindy Bucher; Srdan Verstovsek; John J Wright; Susan R Pilat; Jorge E Cortes; Elihu H Estey; Francis Giles; Miloslav Beran; Said M Sebti
Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(2):509-14.
2008: Apostolia-Maria Tsimberidou; William G Wierda; William Plunkett; Razelle Kurzrock; Susan O'Brien; Sijin Wen; Alessandra Ferrajoli; Farhad Ravandi-Kashani; Guillermo Garcia-Manero; Zeev Estrov; Thomas Kipps; Jennifer R Brown; Albert Fiorentino; Susan Lerner; Hagop M Kantarjian; Michael J Keating
Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(2):196-203.
2007: Cielito C Reyes-Gibby; Margaret Spitz; Xifeng Wu; Kelly Merriman; Carol J Etzel; Eduardo Bruera; Razelle Kurzrock; Sanjay Shete
Cytokine genes and pain severity in lung cancer: exploring the influence of TNF-alpha-308 G/A IL6-174G/C and IL8-251T/A.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2007;16(12):2745-51.
2007: David S Hong; Laura S Angelo; Razelle Kurzrock
Interleukin-6 and its receptor in cancer: implications for translational therapeutics.
Cancer 2007;110(9):1911-28.
2007: Razelle Kurzrock
Studies in target-based treatment.
Molecular cancer therapeutics 2007;6(9):2385.
2007: Bilal Ahmed; Jaime A Tschen; Philip R Cohen; Mohamed H Zaki; Peter L Rady; Stephen K Tyring; Robert Corringham; Razelle Kurzrock
Cutaneous castleman's disease responds to anti interleukin-6 treatment.
Molecular cancer therapeutics 2007;6(9):2386-90.
2007: Lee S Rosen; Razelle Kurzrock; Marilyn Mulay; Andy Van Vugt; Michelle Purdom; Chaan Ng; Jeffrey Silverman; Antonis Koutsoukos; Yu-Nien Sun; Michael B Bass; Ren Y Xu; Anthony Polverino; Jeffrey S Wiezorek; David D Chang; Robert Benjamin; Roy S Herbst
Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(17):2369-76.
2007: Luis H Camacho; Razelle Kurzrock; Alex Cheung; Diane F Barber; Sanjay Gupta; David C Madoff; Michael J Wallace; E Edmund Kim; Steven A Curley; Gabriel N Hortobagyi; Giora Mavligit
Pilot study of regional, hepatic intra-arterial paclitaxel in patients with breast carcinoma metastatic to the liver.
Cancer 2007;109(11):2190-6.
2007: Laura S Angelo; Razelle Kurzrock
Vascular endothelial growth factor and its relationship to inflammatory mediators.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(10):2825-30.
2007: Pierre Fenaux; Azra Raza; Ghulam J Mufti; Carlo Aul; Ulrich Germing; Andrew Lamb; Larry D Cripe; René Kerstens; Peter De Porre; Razelle Kurzrock
A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome.
Blood 2007;109(10):4158-63.
2007: Razelle Kurzrock
I have good news! You have leukemia.
Clinics in dermatology 2007;25(3):350-2.
2007: Philip R Cohen; Razelle Kurzrock
Sarcoidosis and malignancy.
Clinics in dermatology 2007;25(3):326-33.
2007: Razelle Kurzrock
Studies in target-based treatment.
Molecular cancer therapeutics 2007;6(5):1477.
2007: Luis H Camacho; Lisa Marubio; Michelle A Purdom; Deana Leonard; David S Hong; Stacy Moulder; Susan R Pilat; Razelle Kurzrock
Improving the institutional submission and approval process for clinical research protocols in oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(12):1632-3.
2007: Lan Li; Bilal Ahmed; Kapil Mehta; Razelle Kurzrock
Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer.
Molecular cancer therapeutics 2007;6(4):1276-82.
2007: Fadi Braiteh; Razelle Kurzrock
Uncommon tumors and exceptional therapies: paradox or paradigm?
Molecular cancer therapeutics 2007;6(4):1175-9.
2007: Fadi Braiteh; Philip R Cohen; Razelle Kurzrock
CAT scan reveals BAT sign.
Lancet 2007;369(9557):217.
2007: Razelle Kurzrock; Philip R Cohen
Polycystic ovary syndrome in men: Stein-Leventhal syndrome revisited.
Medical hypotheses 2007;68(3):480-3.
2006: Jing Gong; David Yang; Sahar Kohanim; Robin Humphreys; Lyle D Broemeling; Razelle Kurzrock
Novel in vivo imaging shows up-regulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptor agonist antibodies.
Molecular cancer therapeutics 2006;5(12):2991-3000.
2006: Alberto Montero; Zeev Estrov; Emil J Freireich; Issa F Khouri; Charles A Koller; Razelle Kurzrock
Phase II study of low-dose interleukin-11 in patients with myelodysplastic syndrome.
Leukemia & lymphoma 2006;47(10):2049-54.
2006: Fadi Braiteh; Joann T Lim; Razelle Kurzrock
Computed axial tomography scanning (CT scan).
Clinical anatomy (New York, N.Y.) 2006;19(7):682-3.
2006: Sanaz Khanbolooki; Steffan Nawrocki; Thiruvengadam Arumugam; Robert H I Andtbacka; Maria S Pino; Razelle Kurzrock; Craig D Logsdon; James L Abbruzzese; David J McConkey
Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells.
Molecular cancer therapeutics 2006;5(9):2251-60.
2006: Razelle Kurzrock; Moshe Talpaz; Lan Li; Zeev Estrov
Distinct biological impact of dephosphorylation vs. downregulation of p210Bcr-Abl: implications for imatinib mesylate response and resistance.
Leukemia & lymphoma 2006;47(8):1651-64.
2006: Madeleine Duvic; Rakhshandra Talpur; Sijin Wen; Razelle Kurzrock; Cynthia L David; Narin Apisarnthanarax
Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma.
Clinical lymphoma & myeloma 2006;7(1):51-8.
2006: Apostolia-Maria Tsimberidou; Michael J Keating; Carlos E Bueso-Ramos; Razelle Kurzrock
Epstein-Barr virus in patients with chronic lymphocytic leukemia: a pilot study.
Leukemia & lymphoma 2006;47(5):827-36.
2006: Razelle Kurzrock; Farhad Ravandi
Purine analogues in advanced T-cell lymphoid malignancies.
Seminars in hematology 2006;43(2 Suppl 2):S27-34.
2006: Fadi Braiteh; Chaan Ng; Razelle Kurzrock
Refractory Hodgkin lymphoma responds to pentostatin (2'-deoxycoformycin).
Leukemia & lymphoma 2006;47(2):373-5.
2006: Fadi Braiteh; Razelle Kurzrock
CASE 1. Langerhans cell histiocytosis of the thyroid.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(3):522-3.
2005: Fadi Braiteh; Cynthia Boxrud; Bita Esmaeli; Razelle Kurzrock
Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alpha.
Blood 2005;106(9):2992-4.
2005: Lan Li; Fadi S Braiteh; Razelle Kurzrock
Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis.
Cancer 2005;104(6):1322-31.
2005: Doris R Siwak; Shishir Shishodia; Bharat B Aggarwal; Razelle Kurzrock
Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway.
Cancer 2005;104(4):879-90.
2005: Jorge Cortes; Stefan Faderl; Elihu Estey; Razelle Kurzrock; Deborah Thomas; Miloslav Beran; Guillermo Garcia-Manero; Alessandra Ferrajoli; Francis Giles; Charles Koller; Susan O'Brien; John Wright; Stephen A Bai; Andrew Lamb
Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(12):2805-12.
2005: Emil J Freireich; Razelle Kurzrock; Zeev Estrov
Metastasis--an alternative hypothesis.
Cancer 2005;103(8):1537-9.
2005: Razelle Kurzrock; Robert S Benjamin
Risks and benefits of phase 1 oncology trials, revisited.
The New England journal of medicine 2005;352(9):930-2.
2005: Razelle Kurzrock
Farnesyltransferase inhibitors.
Clinical advances in hematology & oncology : H&O 2005;3(3):161-2.
2005: Razelle Kurzrock
Thrombopoietic factors in chronic bone marrow failure states: the platelet problem revisited.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(4):1361-7.
2005: Raoul Tibes; Jonathan Trent; Razelle Kurzrock
Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics.
Annual review of pharmacology and toxicology 2005;45():357-84.
2005: Apostolia-Maria Tsimberidou; Francis Giles; Issa Khouri; Carlos E Bueso-Ramos; Susan R Pilat; Deborah A Thomas; Jorge Cortes; Razelle Kurzrock
Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(1):139-45.
2004: Behnam Ebrahimi; Susan L Tucker; Donghui Li; James L Abbruzzese; Razelle Kurzrock
Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis.
Cancer 2004;101(12):2727-36.
2004: Lan Li; Bharat B Aggarwal; Shishir Shishodia; James L Abbruzzese; Razelle Kurzrock
Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis.
Cancer 2004;101(10):2351-62.
2004: Apostolia-Maria Tsimberidou; Francis Giles; Madeleine Duvic; Razelle Kurzrock
Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas.
Journal of the American Academy of Dermatology 2004;51(2):200-4.
2004: Fedricker Diane Barber; Giora Mavligit; Razelle Kurzrock
Hepatic arterial infusion chemotherapy for metastatic colorectal cancer: a concise overview.
Cancer treatment reviews 2004;30(5):425-36.
2004: Daniel J Lenihan; Alvaro J Alencar; Deborah Yang; Razelle Kurzrock; Michael J Keating; Madeleine Duvic
Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome.
Blood 2004;104(3):655-8.
2004: Razelle Kurzrock; Maher Albitar; Jorge E Cortes; Elihu H Estey; Stefan Faderl; Guillermo Garcia-Manero; Deborah A Thomas; Francis Giles; Mary Ellen Ryback; Alain Thibault; P De Porre; Hagop M Kantarjian
Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(7):1287-92.
2004: Matthew P Thompson; Razelle Kurzrock
Epstein-Barr virus and cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(3):803-21.
2004: Apostolia-Maria Tsimberidou; Francis Giles; Jorge Romaguera; Madeleine Duvic; Razelle Kurzrock
Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignancies.
Cancer 2004;100(3):574-80.
2004: Philip R Cohen; Razelle Kurzrock
Community-acquired methicillin-resistant Staphylococcus aureus skin infection: an emerging clinical problem.
Journal of the American Academy of Dermatology 2004;50(2):277-80.
2004: Apostolia-Maria Tsimberidou; Francis Giles; Madeleine Duvic; Luis Fayad; Razelle Kurzrock
Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series.
Cancer 2004;100(2):342-9.
2003: Razelle Kurzrock; Hagop M Kantarjian; Jorge E Cortes; Neil Singhania; Deborah A Thomas; Edward F Wilson; John J Wright; Emil J Freireich; Moshe Talpaz; Said M Sebti
Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting.
Blood 2003;102(13):4527-34.
2003: Hillary H Wu; Moshe Talpaz; Richard E Champlin; Susan R Pilat; Razelle Kurzrock
Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses.
Cancer 2003;98(11):2410-9.
2003: M P Thompson; Bharat B Aggarwal; S Shishodia; Zeev Estrov; Razelle Kurzrock
Autocrine lymphotoxin production in Epstein-Barr virus-immortalized B cells: induction via NF-kappaB activation mediated by EBV-derived latent membrane protein 1.
Leukemia 2003;17(11):2196-201.
2003: Salim Yazji; Francis Giles; Apostolia-Maria Tsimberidou; Elihu H Estey; Hagop M Kantarjian; S A O'Brien; Razelle Kurzrock
Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes.
Leukemia 2003;17(11):2101-6.
2003: Philip R Cohen; Razelle Kurzrock
Sweet's syndrome revisited: a review of disease concepts.
International journal of dermatology 2003;42(10):761-78.
2003: Eunice Laurent; David L Mitchell; Zeev Estrov; Megan Lowery; Susan L Tucker; Moshe Talpaz; Razelle Kurzrock
Impact of p210(Bcr-Abl) on ultraviolet C wavelength-induced DNA damage and repair.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(10 Pt 1):3722-30.
2003: Alessandra Ferrajoli; Susan M O'Brien; Jorge E Cortes; Francis Giles; Deborah A Thomas; Stefan Faderl; Razelle Kurzrock; Susan Lerner; Dimitrios P Kontoyiannis; Michael J Keating
Phase II study of alemtuzumab in chronic lymphoproliferative disorders.
Cancer 2003;98(4):773-8.
2003: Madeleine Duvic; Narin Apisarnthanarax; Deborah S Cohen; Terry L Smith; Chul Ha; Razelle Kurzrock
Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma.
Journal of the American Academy of Dermatology 2003;49(1):35-49.
2003: Razelle Kurzrock; Hagop M Kantarjian; Brian J Druker; Moshe Talpaz
Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics.
Annals of internal medicine 2003;138(10):819-30.
2003: Jorge Cortes; Maher Albitar; Deborah Thomas; Francis Giles; Razelle Kurzrock; Alain Thibault; Wayne Rackoff; Charles Koller; Susan O'Brien; Guillermo Garcia-Manero; Moshe Talpaz; Andrew Lamb
Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies.
Blood 2003;101(5):1692-7.
2002: Razelle Kurzrock; Jorge Cortes; Andrew Lamb
Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome.
Seminars in hematology 2002;39(4 Suppl 3):20-4.
2002: Apostolia-Maria Tsimberidou; Deborah Thomas; Susan O'Brien; Michael Andreeff; Razelle Kurzrock; Michael Keating; Maher Albitar; Andrew Lamb; Francis Giles
Recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein Enbrel in patients with refractory hematologic malignancies.
Cancer chemotherapy and pharmacology 2002;50(3):237-42.
2002: Alessandra Ferrajoli; Michael J Keating; Taghi Manshouri; Francis Giles; Amanda Dey; Zeev Estrov; Charles Koller; Razelle Kurzrock; Deborah A Thomas; Stefan Faderl; Susan Lerner; Susan O'Brien; Maher Albitar
The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia.
Blood 2002;100(4):1215-9.
2002: Keding Cheng; Razelle Kurzrock; Xiangguo Qiu; Zeev Estrov; Stella Ku; Kim M Dulski; Jean Y J Wang; Moshe Talpaz
Reduced focal adhesion kinase and paxillin phosphorylation in BCR-ABL-transfected cells.
Cancer 2002;95(2):440-50.
2002: Hagop M Kantarjian; Jorge E Cortes; Jacob M Rowe; Razelle Kurzrock
Future clinical implications for farnesyltransferase inhibitors in hematologic malignancies.
Seminars in hematology 2002;39(3 Suppl 2):36-8.
2002: Jorge E Cortes; Razelle Kurzrock; Hagop M Kantarjian
Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies.
Seminars in hematology 2002;39(3 Suppl 2):26-30.
2002: Razelle Kurzrock
Myelodysplastic syndrome overview.
Seminars in hematology 2002;39(3 Suppl 2):18-25.
2002: Laura S Angelo; Moshe Talpaz; Razelle Kurzrock
Autocrine interleukin-6 production in renal cell carcinoma: evidence for the involvement of p53.
Cancer research 2002;62(3):932-40.
2002: Philip R Cohen; Razelle Kurzrock
Sweet's syndrome: a review of current treatment options.
American journal of clinical dermatology 2002;3(2):117-31.
2001: Razelle Kurzrock; Jorge Cortes; Deborah A Thomas; Sima Jeha; Susan R Pilat; Moshe Talpaz
Pilot study of low-dose interleukin-11 in patients with bone marrow failure.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(21):4165-72.
2001: Razelle Kurzrock
The role of cytokines in cancer-related fatigue.
Cancer 2001;92(6 Suppl):1684-8.
2001: Razelle Kurzrock
Therapy of T cell lymphomas with pentostatin.
Annals of the New York Academy of Sciences 2001;941():200-5.
2001: Razelle Kurzrock; Carlos E Bueso-Ramos; Andrew Lamb; Emil J Freireich; Susan L Tucker; Michael J Siciliano; Susan R Pilat; Moshe Talpaz
BCR rearrangement-negative chronic myelogenous leukemia revisited.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(11):2915-26.
2001: Eunice Laurent; Moshe Talpaz; Andrew Lamb; Razelle Kurzrock
The BCR gene and philadelphia chromosome-positive leukemogenesis.
Cancer research 2001;61(6):2343-55.
2001: Luis Fayad; Michael J Keating; James M Reuben; Susan O'Brien; Bang-Ning Lee; Susan Lerner; Razelle Kurzrock
Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome.
Blood 2001;97(1):256-63.
2000: Eunice Laurent; Moshe Talpaz; M Wetzler; Razelle Kurzrock
Cytoplasmic and nuclear localization of the 130 and 160 kDa Bcr proteins.
Leukemia 2000;14(11):1892-7.
2000: Razelle Kurzrock
rhIL-11 for the prevention of dose-limiting chemotherapy-induced thrombocytopenia.
Oncology (Williston Park, N.Y.) 2000;14(9 Suppl 8):9-11.
2000: Moshe Talpaz; X Qiu; Keding Cheng; Jorge E Cortes; Andrew Lamb; Razelle Kurzrock
Autoantibodies to Abl and Bcr proteins.
Leukemia 2000;14(9):1661-6.
2000: Philip R Cohen; Razelle Kurzrock
Sweet's syndrome: a neutrophilic dermatosis classically associated with acute onset and fever.
Clinics in dermatology 2000;18(3):265-82.
2000: Razelle Kurzrock
Pentostatin (Nipent) in T-cell lymphomas.
Seminars in oncology 2000;27(2 Suppl 5):64-6.
1999: Farhad Ravandi; Zeev Estrov; Razelle Kurzrock; J B Breitmeyer; B J Maschek; Moshe Talpaz
A phase I study of recombinant interferon-beta in patients with advanced malignant disease.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(12):3990-8.
1999: Francis Giles; A R Keating; Razelle Kurzrock; Moshe Talpaz
A pilot study of recombinant human interleukin-4 therapy of myelofibrosis.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 1999;19(11):1253-5.
1999: Razelle Kurzrock; Susan R Pilat; Madeleine Duvic
Pentostatin therapy of T-cell lymphomas with cutaneous manifestations.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(10):3117-21.
1999: Stefan Faderl; Moshe Talpaz; Zeev Estrov; Susan O'Brien; Razelle Kurzrock; Hagop M Kantarjian
The biology of chronic myeloid leukemia.
The New England journal of medicine 1999;341(3):164-72.
1999: DM Beaupre; Moshe Talpaz; Frank C Marini; Richard J Cristiano; Jack A Roth; Zeev Estrov; Maher Albitar; M H Freedman; Razelle Kurzrock
Autocrine interleukin-1beta production in leukemia: evidence for the involvement of mutated RAS.
Cancer research 1999;59(12):2971-80.
1999: E Diamandidou; MI Colome; Luis Fayad; Madeleine Duvic; Razelle Kurzrock
Prognostic factor analysis in mycosis fungoides/Sézary syndrome.
Journal of the American Academy of Dermatology 1999;40(6 Pt 1):914-24.
1999: DM Beaupre; Razelle Kurzrock
RAS and leukemia: from basic mechanisms to gene-directed therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(3):1071-9.
1999: DM Beaupre; Razelle Kurzrock
RAS inhibitors in hematologic cancers: biologic considerations and clinical applications.
Investigational new drugs 1999;17(2):137-43.
1998: E Diamandidou; MI Colome-Grimmer; Luis Fayad; Madeleine Duvic; Razelle Kurzrock
Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis.
Blood 1998;92(4):1150-9.
1998: Luis Fayad; Fernando Cabanillas; Moshe Talpaz; Peter McLaughlin; Razelle Kurzrock
High serum interleukin-6 levels correlate with a shorter failure-free survival in indolent lymphoma.
Leukemia & lymphoma 1998;30(5-6):563-71.
1998: Alessandra Ferrajoli; Moshe Talpaz; Razelle Kurzrock; David Harris; Quin Van; Elihu H Estey; Zeev Estrov
Thrombopoietin stimulates myelodysplastic syndrome granulocyte-macrophage and erythroid progenitor proliferation.
Leukemia & lymphoma 1998;30(3-4):279-92.
1998: Zeev Estrov; Moshe Talpaz; Stella Ku; David Harris; Quin Van; Miloslav Beran; Cheryl Hirsch-Ginsberg; Yang Huh; G Yee; Razelle Kurzrock
Z-138: a new mature B-cell acute lymphoblastic leukemia cell line from a patient with transformed chronic lymphocytic leukemia.
Leukemia research 1998;22(4):341-53.
1998: Razelle Kurzrock; Zeev Estrov; Andrew Lamb; Moshe Talpaz
Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(4):1526-31.
1998: Razelle Kurzrock; Zeev Estrov; Stella Ku; M Leonard; Moshe Talpaz
Interleukin-1 increases expression of the LYT-10 (NFkappaB2) proto-oncogene/transcription factor in renal cell carcinoma lines.
The Journal of laboratory and clinical medicine 1998;131(3):261-8.
1998: Razelle Kurzrock; Moshe Talpaz; Miloslav Beran; David Harris; Zeev Estrov
DNA in situ hybridization of individual colonies to determine lineage derivation in leukemia.
Leukemia 1998;12(2):242-6.
1997: Hagop M Kantarjian; Moshe Talpaz; Susan O'Brien; Razelle Kurzrock; Jordan U Gutterman; Michael J Keating; K B McCredie; Emil J Freireich
Chronic myelogenous leukemia--progress at the M. D. Anderson Cancer Center over the past two decades and future directions: first Emil J Freireich Award Lecture.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(12 Pt 2):2723-33.
1997: Razelle Kurzrock
Cytokine deregulation in hematological malignancies: clinical and biological implications.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(12 Pt 2):2581-4.
1997: H Alejandro Preti; Fernando Cabanillas; Moshe Talpaz; S L Tucker; J F Seymour; Razelle Kurzrock
Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma.
Annals of internal medicine 1997;127(3):186-94.
1997: Jorge Cortes; Razelle Kurzrock
Interleukin-10 in non-Hodgkin's lymphoma.
Leukemia & lymphoma 1997;26(3-4):251-9.
1997: Moshe Talpaz; Hagop M Kantarjian; Susan O'Brien; Razelle Kurzrock
The M.D. Anderson Cancer Center experience with interferon-alpha therapy in chronic myelogenous leukaemia.
Baillière's clinical haematology 1997;10(2):291-305.
1997: Philip R Cohen; Razelle Kurzrock
Mucocutaneous paraneoplastic syndromes.
Seminars in oncology 1997;24(3):334-59.
1997: Razelle Kurzrock; Sara S Strom; Elihu Estey; Susan O'Brien; Michael J Keating; H Jiang; T Adams; Moshe Talpaz
Second cancer risk in hairy cell leukemia: analysis of 350 patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(5):1803-10.
1997: H Gisslinger; Razelle Kurzrock; M Wetzler; S Tucker; Andrew Lamb; B Robertson; Moshe Talpaz
Apoptosis in chronic myelogenous leukemia: studies of stage-specific differences.
Leukemia & lymphoma 1997;25(1-2):121-33.
1997: J F Seymour; Moshe Talpaz; F B Hagemeister; F Cabanillas; Razelle Kurzrock
Clinical correlates of elevated serum levels of interleukin 6 in patients with untreated Hodgkin's disease.
The American journal of medicine 1997;102(1):21-8.
1997: J F Seymour; Moshe Talpaz; Razelle Kurzrock
Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow-up.
Leukemia 1997;11(1):42-7.
1996: E Diamandidou; Philip R Cohen; Razelle Kurzrock
Mycosis fungoides and Sezary syndrome.
Blood 1996;88(7):2385-409.
1996: Zeev Estrov; Moshe Talpaz; S Ku; David Harris; Ruth Lapushin; Charles Koller; C Hirsh-Ginsberg; Y Huh; G Yee; Razelle Kurzrock
Molecular and biologic characterization of a newly established Philadelphia-positive acute lymphoblastic leukemia cell line (Z-33) with an autocrine response to GM-CSF.
Leukemia 1996;10(9):1534-43.
1996: Madeleine Duvic; N A Lemak; J R Redman; Patricia J Eifel; Susan L Tucker; Fernando Cabanillas; Razelle Kurzrock
Combined modality therapy for cutaneous T-cell lymphoma.
Journal of the American Academy of Dermatology 1996;34(6):1022-9.
1996: P Kellokumpu-Lehtinen; Moshe Talpaz; David Harris; Quin Van; Razelle Kurzrock; Zeev Estrov
Leukemia-inhibitory factor stimulates breast, kidney and prostate cancer cell proliferation by paracrine and autocrine pathways.
International journal of cancer. Journal international du cancer 1996;66(4):515-9.
1996: Elihu Estey; Peter F Thall; Kapil Mehta; M Rosenblum; T Brewer; V Simmons; Fernando Cabanillas; Razelle Kurzrock; Gabriel Lopez-Berestein
Alterations in tretinoin pharmacokinetics following administration of liposomal all-trans retinoic acid.
Blood 1996;87(9):3650-4.
1996: Zeev Estrov; Moshe Talpaz; Theodore F Zipf; Hagop M Kantarjian; S Ku; M V Ouspenskaia; Cheryl Hirsch-Ginsberg; Y Huh; G Yee; Razelle Kurzrock
Role of granulocyte-macrophage colony-stimulating factor in Philadelphia (Ph1)-positive acute lymphoblastic leukemia: studies on two newly established Ph1-positive acute lymphoblastic leukemia cell lines (Z-119 and Z-181).
Journal of cellular physiology 1996;166(3):618-30.
1995: B S Andersson; V P Collins; Razelle Kurzrock; D W Larkin; C Childs; A Ost; A Cork; J M Trujillo; Emil J Freireich; Michael J Siciliano
KBM-7, a human myeloid leukemia cell line with double Philadelphia chromosomes lacking normal c-ABL and BCR transcripts.
Leukemia 1995;9(12):2100-8.
1995: Razelle Kurzrock; Philip R Cohen
Cutaneous paraneoplastic syndromes in solid tumors.
The American journal of medicine 1995;99(6):662-71.
1995: Zeev Estrov; B Samal; Ruth Lapushin; P Kellokumpu-Lehtinen; A A Sahin; Razelle Kurzrock; Moshe Talpaz; Bharat B Aggarwal
Leukemia inhibitory factor binds to human breast cancer cells and stimulates their proliferation.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 1995;15(10):905-13.
1995: Razelle Kurzrock; Meir Wetzler; Zeev Estrov; Moshe Talpaz
Interleukin-1 and its inhibitors: a biologic and therapeutic model for the role of growth regulatory factors in leukemias.
Cytokines and molecular therapy 1995;1(3):177-84.
1995: Meir Wetzler; Razelle Kurzrock; AM Goodacre; Peter McLaughlin; S Ku; Moshe Talpaz
Transformation of chronic lymphocytic leukemia to lymphoma of true histiocytic type.
Cancer 1995;76(4):609-17.
1995: Razelle Kurzrock; Philip R Cohen
Mucocutaneous paraneoplastic manifestations of hematologic malignancies.
The American journal of medicine 1995;99(2):207-16.
1995: Zeev Estrov; Razelle Kurzrock; Moshe Talpaz
Cytokines and their antagonists in myeloid disorders.
Seminars in hematology 1995;32(3):220-31.
1995: Zeev Estrov; Moshe Talpaz; G Mavligit; R Pazdur; David Harris; S M Greenberg; Razelle Kurzrock
Elevated plasma thrombopoietic activity in patients with metastatic cancer-related thrombocytosis.
The American journal of medicine 1995;98(6):551-8.
1995: J F Seymour; Elihu H Estey; M J Keating; Razelle Kurzrock
Response to interferon-alpha in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine.
Leukemia 1995;9(5):929-32.
1995: J E Cortes; Moshe Talpaz; Fernando Cabanillas; J F Seymour; Razelle Kurzrock
Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis.
Blood 1995;85(9):2516-20.
1995: Meir Wetzler; Moshe Talpaz; G Yee; Sanford A Stass; R A Van Etten; M Andreeff; AM Goodacre; H D Kleine; R K Mahadevia; Razelle Kurzrock
Cell cycle-related shifts in subcellular localization of BCR: association with mitotic chromosomes and with heterochromatin.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(8):3488-92.
1995: J F Seymour; Moshe Talpaz; Fernando Cabanillas; Meir Wetzler; Razelle Kurzrock
Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(3):575-82.
1995: Razelle Kurzrock; Philip R Cohen
Erythema gyratum repens.
JAMA : the journal of the American Medical Association 1995;273(7):594.
1995: Razelle Kurzrock; S Ku; Moshe Talpaz
Abnormalities in the PRAD1 (CYCLIN D1/BCL-1) oncogene are frequent in cervical and vulvar squamous cell carcinoma cell lines.
Cancer 1995;75(2):584-90.
1995: Meir Wetzler; Razelle Kurzrock; Zeev Estrov; Elihu Estey; Moshe Talpaz
Cytokine expression in adherent layers from patients with myelodysplastic syndrome and acute myelogenous leukemia.
Leukemia research 1995;19(1):23-34.
1994: Meir Wetzler; Razelle Kurzrock; Zeev Estrov; Andrew Lamb; H Gisslinger; M P Underbrink; Moshe Talpaz
Altered levels of interleukin-1 beta and interleukin-1 receptor antagonist in chronic myelogenous leukemia: clinical and prognostic correlates.
Blood 1994;84(9):3142-7.
1994: A Ferrajoli; Moshe Talpaz; N G Ordonez; E Richard Stanley; Cheryl Hirsch-Ginsberg; Theodore F Zipf; Meir Wetzler; Razelle Kurzrock; Zeev Estrov
Interleukin 4 alters human bone marrow stroma and modulates its interaction with hematopoietic progenitors.
Stem cells (Dayton, Ohio) 1994;12(6):638-49.
1994: Moshe Talpaz; Zeev Estrov; Andrew Lamb; S Ku; A Foteh; Razelle Kurzrock
Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies.
The Journal of clinical investigation 1994;94(4):1383-9.
1994: Susan O'Brien; Razelle Kurzrock; Madeleine Duvic; Andrew Lamb; Sanford A Stass; LE Robertson; Elihu Estey; Sherry Pierce; Michael J Keating
2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders.
Blood 1994;84(3):733-8.
1994: J F Seymour; Razelle Kurzrock; Emil J Freireich; Elihu H Estey
2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia.
Blood 1994;83(10):2906-11.
1994: Meir Wetzler; Zeev Estrov; Moshe Talpaz; K J Kim; M Alphonso; R Srinivasan; Razelle Kurzrock
Leukemia inhibitory factor in long-term adherent layer cultures: increased levels of bioactive protein in leukemia and modulation by IL-4, IL-1 beta, and TNF-alpha.
Cancer research 1994;54(7):1837-42.
1994: Razelle Kurzrock; Philip R Cohen; A Markowitz
Clinical manifestations of vasculitis in patients with solid tumors. A case report and review of the literature.
Archives of internal medicine 1994;154(3):334-40.
1993: Meir Wetzler; Moshe Talpaz; R A Van Etten; C Hirsh-Ginsberg; Miloslav Beran; Razelle Kurzrock
Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation.
The Journal of clinical investigation 1993;92(4):1925-39.
1993: M Wetzler; Zeev Estrov; Moshe Talpaz; A Markowitz; Jordan U Gutterman; Razelle Kurzrock
Granulocyte-macrophage colony-stimulating factor as a cause of paraneoplastic leukaemoid reaction in advanced transitional cell carcinoma.
Journal of internal medicine 1993;234(4):417-20.
1993: Zeev Estrov; Razelle Kurzrock; Moshe Talpaz
Role of interleukin-1 inhibitory molecules in therapy of acute and chronic myelogenous leukemia.
Leukemia & lymphoma 1993;10(6):407-18.
1993: Miloslav Beran; Pavel Pisa; Susan O'Brien; Razelle Kurzrock; Michael J Siciliano; A Cork; B S Andersson; V Kohli; Andrew Lamb
Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase.
Cancer research 1993;53(15):3603-10.
1993: Hagop M Kantarjian; Albert Deisseroth; Razelle Kurzrock; Zeev Estrov; Moshe Talpaz
Chronic myelogenous leukemia: a concise update.
Blood 1993;82(3):691-703.
1993: Razelle Kurzrock; Elihu Estey; Moshe Talpaz
All-trans retinoic acid: tolerance and biologic effects in myelodysplastic syndrome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(8):1489-95.
1993: Zeev Estrov; Moshe Talpaz; Hagop M Kantarjian; Theodore F Zipf; K L McClain; Razelle Kurzrock
Heterogeneity in lineage derivation of Philadelphia-positive acute lymphoblastic leukemia expressing p190BCR-ABL or p210BCR-ABL: determination by analysis of individual colonies with the polymerase chain reaction.
Cancer research 1993;53(14):3289-93.
1993: Razelle Kurzrock; J Redman; Fernando Cabanillas; D Jones; J Rothberg; Moshe Talpaz
Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms.
Cancer research 1993;53(9):2118-22.
1993: A Ferrajoli; Moshe Talpaz; Razelle Kurzrock; Zeev Estrov
Analysis of the effects of tumor necrosis factor inhibitors on human hematopoiesis.
Stem cells (Dayton, Ohio) 1993;11(2):112-9.
1993: Zeev Estrov; Razelle Kurzrock; E Pocsik; Sen Pathak; H M Kantarjian; Theodore F Zipf; D Harris; Moshe Talpaz; Bharat B Aggarwal
Lymphotoxin is an autocrine growth factor for Epstein-Barr virus-infected B cell lines.
The Journal of experimental medicine 1993;177(3):763-74.
1993: Zeev Estrov; A B Markowitz; Razelle Kurzrock; Meir Wetzler; Hagop M Kantarjian; A Ferrajoli; Jordan U Gutterman; Moshe Talpaz
Suppression of chronic myelogenous leukemia colony growth by interleukin-4.
Leukemia 1993;7(2):214-20.
1993: Razelle Kurzrock; Andrew Lamb; Meir Wetzler; Zeev Estrov; Elihu Estey; K Troutman-Worden; Jordan U Gutterman; Moshe Talpaz
Ubiquitous expression of cytokines in diverse leukemias of lymphoid and myeloid lineage.
Experimental hematology 1993;21(1):80-5.
1993: Razelle Kurzrock; Philip R Cohen
Paraneoplastic erythromelalgia.
Clinics in dermatology 1993;11(1):73-82.
1993: Razelle Kurzrock; Philip R Cohen
Vasculitis and cancer.
Clinics in dermatology 1993;11(1):175-87.
1993: Meir Wetzler; Moshe Talpaz; Zeev Estrov; Razelle Kurzrock
CML: mechanisms of disease initiation and progression.
Leukemia & lymphoma 1993;11 Suppl 1():47-50.
1992: Zeev Estrov; Moshe Talpaz; Meir Wetzler; Razelle Kurzrock
The modulatory hematopoietic activities of leukemia inhibitory factor.
Leukemia & lymphoma 1992;8(1-2):1-7.
1992: Kapil Dhingra; Razelle Kurzrock; Andrew Lamb; R Baine; P S Eastman; S Ku; Jordan U Gutterman; Moshe Talpaz
Minimal residual disease in interferon-treated chronic myelogenous leukemia: results and pitfalls of analysis based on polymerase chain reaction.
Leukemia 1992;6(8):754-60.
1992: Zeev Estrov; C H Park; C L Reading; Elihu H Estey; Moshe Talpaz; Razelle Kurzrock; Albert Deisseroth; Jordan U Gutterman
The effect of granulocyte-macrophage colony-stimulating factor on undifferentiated and mature acute myelogenous leukemia blast progenitors.
Experimental hematology 1992;20(7):886-90.
1992: Razelle Kurzrock; Moshe Talpaz; Jordan U Gutterman
Very low doses of GM-CSF administered alone or with erythropoietin in aplastic anemia.
The American journal of medicine 1992;93(1):41-8.
1992: Zeev Estrov; Elihu H Estey; Michael Andreeff; Moshe Talpaz; Razelle Kurzrock; C L Reading; Albert Deisseroth; Jordan U Gutterman
Comparison of in vivo and in vitro effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with acute myeloid leukemia.
Experimental hematology 1992;20(5):558-64.
1992: M Wetzler; Moshe Talpaz; M J Kellagher; Jordan U Gutterman; Razelle Kurzrock
Myelokathexis: normalization of neutrophil counts and morphology by GM-CSF.
JAMA : the journal of the American Medical Association 1992;267(16):2179-80.
1992: Zeev Estrov; Razelle Kurzrock; Elihu Estey; Meir Wetzler; A Ferrajoli; David Harris; M Blake; Jordan U Gutterman; Moshe Talpaz
Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors.
Blood 1992;79(8):1938-45.
1992: Moshe Talpaz; Y Chernajovsky; K Troutman-Worden; Meir Wetzler; Andrew Lamb; Jordan U Gutterman; Razelle Kurzrock
Interferon-stimulated genes in interferon-sensitive and -resistant chronic myelogenous leukemia patients.
Cancer research 1992;52(5):1087-90.
1992: Elihu H Estey; Razelle Kurzrock; Hagop M Kantarjian; Susan M O'Brien; K B McCredie; Miloslav Beran; Charles Koller; Michael J Keating; Cheryl Hirsch-Ginsberg; Y O Huh
Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA).
Blood 1992;79(4):882-7.
1992: Moshe Talpaz; Andrew Lamb; Razelle Kurzrock; Jordan U Gutterman
Bone marrow hypoplasia and aplasia complicating interferon therapy for chronic myelogenous leukemia.
Cancer 1992;69(2):410-2.
1991: Zeev Estrov; Razelle Kurzrock; Moshe Talpaz; M Blake; Jordan U Gutterman
Granulocyte-macrophage colony-stimulating factor and interleukin-3 in combination: a potent and consistent myelodysplastic syndrome bone marrow stimulant in vitro.
Annals of hematology 1991;63(6):297-301.
1991: Moshe Talpaz; Razelle Kurzrock; Andrew Lamb; J Rothberg; S Saks; L Evans; Jordan U Gutterman
A phase II study alternating alpha-2a-interferon and gamma-interferon therapy in patients with chronic myelogenous leukemia.
Cancer 1991;68(10):2125-30.
1991: Razelle Kurzrock; Moshe Talpaz; Elihu Estey; Susan O'Brien; Zeev Estrov; Jordan U Gutterman
Erythropoietin treatment in patients with myelodysplastic syndrome and anemia.
Leukemia 1991;5(11):985-90.
1991: Hagop M Kantarjian; Moshe Talpaz; Kapil Dhingra; Elihu Estey; Michael J Keating; S Ku; J Trujillo; Y Huh; Sanford A Stass; Razelle Kurzrock
Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia.
Blood 1991;78(9):2411-8.
1991: Meir Wetzler; Razelle Kurzrock; D G Lowe; Andrew Lamb; Jordan U Gutterman; Moshe Talpaz
Alteration in bone marrow adherent layer growth factor expression: a novel mechanism of chronic myelogenous leukemia progression.
Blood 1991;78(9):2400-6.
1991: Razelle Kurzrock; Philip R Cohen
Erythromelalgia: review of clinical characteristics and pathophysiology.
The American journal of medicine 1991;91(4):416-22.
1991: Moshe Talpaz; Andrew Lamb; Razelle Kurzrock; Jordan U Gutterman
Interferon alpha in the therapy of CML.
British journal of haematology 1991;79 Suppl 1():38-41.
1991: Razelle Kurzrock; Moshe Talpaz
The molecular pathology of chronic myelogenous leukaemia.
British journal of haematology 1991;79 Suppl 1():34-7.
1991: P J Schilling; Razelle Kurzrock; Andrew Lamb; Jordan U Gutterman; Moshe Talpaz
Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia.
Cancer 1991;68(7):1536-7.
1991: Razelle Kurzrock; Moshe Talpaz; Jordan U Gutterman
Hairy cell leukaemia: review of treatment.
British journal of haematology 1991;79 Suppl 1():17-20.
1991: Zeev Estrov; Razelle Kurzrock; Meir Wetzler; Andrew Lamb; M Blake; David Harris; Jordan U Gutterman; Moshe Talpaz
Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity.
Blood 1991;78(6):1476-84.
1991: Razelle Kurzrock; Zeev Estrov; Meir Wetzler; Jordan U Gutterman; Moshe Talpaz
LIF: not just a leukemia inhibitory factor.
Endocrine reviews 1991;12(3):208-17.
1991: Razelle Kurzrock; Moshe Talpaz; Zeev Estrov; Michael G Rosenblum; Jordan U Gutterman
Phase I study of recombinant human interleukin-3 in patients with bone marrow failure.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(7):1241-50.
1991: Razelle Kurzrock; Moshe Talpaz; J A Gomez; Elihu H Estey; Susan O'Brien; Cheryl Hirsch-Ginsberg; Charles Koller; Emil J Freireich; Jordan U Gutterman
Differential dose-related haematological effects of GM-CSF in pancytopenia: evidence supporting the advantage of low- over high-dose administration in selected patients.
British journal of haematology 1991;78(3):352-8.
1991: Meir Wetzler; Moshe Talpaz; D G Lowe; G Baiocchi; Jordan U Gutterman; Razelle Kurzrock
Constitutive expression of leukemia inhibitory factor RNA by human bone marrow stromal cells and modulation by IL-1, TNF-alpha, and TGF-beta.
Experimental hematology 1991;19(5):347-51.
1991: Moshe Talpaz; Andrew Lamb; Razelle Kurzrock; J M Trujillo; Jordan U Gutterman
Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients.
Annals of internal medicine 1991;114(7):532-8.
1991: Kapil Dhingra; Moshe Talpaz; Andrew Lamb; S Ku; J Rothberg; Jordan U Gutterman; Razelle Kurzrock
Appearance of acute leukemia-associated P190BCR-ABL in chronic myelogenous leukemia may correlate with disease progression.
Leukemia 1991;5(3):191-5.
1991: Elihu H Estey; Razelle Kurzrock; Moshe Talpaz; K B McCredie; Susan O'Brien; Hagop M Kantarjian; Michael J Keating; Albert Deisseroth; Jordan U Gutterman
Effects of low doses of recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with myelodysplastic syndromes.
British journal of haematology 1991;77(3):291-5.
1991: G Baiocchi; John J Kavanagh; Moshe Talpaz; J Taylor Wharton; Jordan U Gutterman; Razelle Kurzrock
Expression of the macrophage colony-stimulating factor and its receptor in gynecologic malignancies.
Cancer 1991;67(4):990-6.
1991: Zeev Estrov; Moshe Talpaz; T C Chou; Razelle Kurzrock; M Blake; Jordan U Gutterman
Synergistic antiproliferative effect of interferon alpha and azidothymidine in chronic myelogenous leukemia.
Leukemia 1991;5(2):101-7.
1991: Kapil Dhingra; Moshe Talpaz; M G Riggs; P S Eastman; Theodore F Zipf; S Ku; Razelle Kurzrock
Hybridization protection assay: a rapid, sensitive, and specific method for detection of Philadelphia chromosome-positive leukemias.
Blood 1991;77(2):238-42.
1991: Razelle Kurzrock; Zeev Estrov; Moshe Talpaz; Jordan U Gutterman
Cytokines in tumor therapy. Interleukin-3.
American journal of clinical oncology 1991;14 Suppl 1():S45-50.
1990: M Wetzler; Moshe Talpaz; Eugenie S Kleinerman; A King; Y O Huh; Jordan U Gutterman; Razelle Kurzrock
A new familial immunodeficiency disorder characterized by severe neutropenia, a defective marrow release mechanism, and hypogammaglobulinemia.
The American journal of medicine 1990;89(5):663-72.
1990: Meir Wetzler; Razelle Kurzrock; K Taylor; G Spitzer; Andrew Lamb; G Baiocchi; S Ku; Jordan U Gutterman; Moshe Talpaz
Constitutive and induced expression of growth factors in normal and chronic phase chronic myelogenous leukemia Ph1 bone marrow stroma.
Cancer research 1990;50(18):5801-5.
1990: Jordan U Gutterman; Saroj Vadhan-Raj; C Logothetis; E Anaissle; Elihu Estey; Moshe Talpaz; Razelle Kurzrock
Effects of granulocyte-macrophage colony-stimulating factor in iatrogenic myelosuppression, bone marrow failure, and regulation of host defense.
Seminars in hematology 1990;27(3 Suppl 3):15-24.
1990: Moshe Talpaz; Andrew Lamb; Razelle Kurzrock; Jordan U Gutterman
Update on therapeutic options for chronic myelogenous leukemia.
Seminars in hematology 1990;27(3 Suppl 4):31-6.
1990: Hagop M Kantarjian; Raymond Alexanian; Charles Koller; Razelle Kurzrock; Michael J Keating
Fludarabine therapy in macroglobulinemic lymphoma.
Blood 1990;75(10):1928-31.
1990: Elihu H Estey; D Dixon; Hagop M Kantarjian; Michael J Keating; K McCredie; Gerald P Bodey; Razelle Kurzrock; Moshe Talpaz; Emil J Freireich; Albert Deisseroth
Treatment of poor-prognosis, newly diagnosed acute myeloid leukemia with ara-C and recombinant human granulocyte-macrophage colony-stimulating factor.
Blood 1990;75(9):1766-9.
1990: Hagop M Kantarjian; Razelle Kurzrock; Moshe Talpaz
Philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia.
Hematology/oncology clinics of North America 1990;4(2):389-404.
1990: Razelle Kurzrock; Hagop M Kantarjian; M Shtalrid; Jordan U Gutterman; Moshe Talpaz
Philadelphia chromosome-negative chronic myelogenous leukemia without breakpoint cluster region rearrangement: a chronic myeloid leukemia with a distinct clinical course.
Blood 1990;75(2):445-52.
1990: David F Claxton; Andrew Lamb; Razelle Kurzrock; J M Trujillo; Jordan U Gutterman; Moshe Talpaz
Alpha interferon dose-dependent suppression of secondary clones in a patient with Philadelphia-positive chronic myelogenous leukemia.
Acta haematologica 1990;83(3):149-51.
1989: Razelle Kurzrock; B Feinberg; Moshe Talpaz; S Saks; Jordan U Gutterman
Phase I study of a combination of recombinant tumor necrosis factor-alpha and recombinant interferon-gamma in cancer patients.
Journal of interferon research 1989;9(4):435-44.
1989: Moshe Talpaz; Razelle Kurzrock; Andrew Lamb; Susan O'Brien; Jordan U Gutterman
Recombinant interferon-alpha therapy of Philadelphia chromosome-negative myeloproliferative disorders with thrombocytosis.
The American journal of medicine 1989;86(5):554-8.
1989: Moshe Talpaz; Razelle Kurzrock; Andrew Lamb; Jordan U Gutterman
Therapy of chronic myelogenous leukaemia with interferons.
Cancer surveys 1989;8(4):793-8.
1989: Razelle Kurzrock; Philip R Cohen
Erythromelalgia and myeloproliferative disorders.
Archives of internal medicine 1989;149(1):105-9.
1989: Moshe Talpaz; Andrew Lamb; Razelle Kurzrock; Jordan U Gutterman
Clinical studies with interferons in Philadelphia positive chronic myelogenous leukemia.
Bone marrow transplantation 1989;4 Suppl 1():63.
1989: Razelle Kurzrock; Jordan U Gutterman; Andrew Lamb; Moshe Talpaz
Therapy of chronic myelogenous leukemia with interferon.
Cancer investigation 1989;7(1):83-91.
1988: Hagop M Kantarjian; M Shtalrid; Razelle Kurzrock; M Blick; W T Dalton; A LeMaistre; Sanford A Stass; K B McCredie; Jordan U Gutterman; Emil J Freireich
Significance and correlations of molecular analysis results in patients with Philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia.
The American journal of medicine 1988;85(5):639-44.
1988: Razelle Kurzrock; Jordan U Gutterman; Moshe Talpaz
The molecular genetics of Philadelphia chromosome-positive leukemias.
The New England journal of medicine 1988;319(15):990-8.
1988: M Shtalrid; Moshe Talpaz; M Blick; P Romero; Andrew Lamb; K Taylor; J Trujillo; J Schachner; Jordan U Gutterman; Razelle Kurzrock
Philadelphia-negative chronic myelogenous leukemia with breakpoint cluster region rearrangement: molecular analysis, clinical characteristics, and response to therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(10):1569-75.
1988: J R Quesada; R Alexanian; Razelle Kurzrock; Bart Barlogie; S Saks; Jordan U Gutterman
Recombinant interferon gamma in hairy cell leukemia, multiple myeloma, and Waldenstrom's macroglobulinemia.
American journal of hematology 1988;29(1):1-4.
1988: B Feinberg; Razelle Kurzrock; Moshe Talpaz; M Blick; S Saks; Jordan U Gutterman
A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(8):1328-34.
1988: M Shtalrid; Moshe Talpaz; Razelle Kurzrock; Andrew Lamb; J Trujillo; Jordan U Gutterman; G Yoffe; M Blick
Analysis of breakpoints within the bcr gene and their correlation with the clinical course of Philadelphia-positive chronic myelogenous leukemia.
Blood 1988;72(2):485-90.
1988: Moshe Talpaz; H M Kantarjian; Razelle Kurzrock; Jordan U Gutterman
Therapy of chronic myelogenous leukemia: chemotherapy and interferons.
Seminars in hematology 1988;25(1):62-73.
1987: Razelle Kurzrock; M Shtalrid; Moshe Talpaz; W S Kloetzer; Jordan U Gutterman
Expression of c-abl in Philadelphia-positive acute myelogenous leukemia.
Blood 1987;70(5):1584-8.
1987: Razelle Kurzrock; Moshe Talpaz; Andrew Lamb; R Walters; S Saks; J M Trujillo; Jordan U Gutterman
Therapy of chronic myelogenous leukemia with recombinant interferon-gamma.
Blood 1987;70(4):943-7.
1987: Razelle Kurzrock; M Shtalrid; Jordan U Gutterman; Charles Koller; R Walters; J M Trujillo; Moshe Talpaz
Molecular analysis of chromosome 22 breakpoints in adult Philadelphia-positive acute lymphoblastic leukaemia.
British journal of haematology 1987;67(1):55-9.
1987: M Blick; P Romero; Moshe Talpaz; Razelle Kurzrock; M Shtalrid; B Andersson; J Trujillo; Miloslav Beran; Jordan U Gutterman
Molecular characteristics of chronic myelogenous leukemia in blast crisis.
Cancer genetics and cytogenetics 1987;27(2):349-56.
1987: Razelle Kurzrock; W S Kloetzer; Moshe Talpaz; M Blick; R Walters; R B Arlinghaus; Jordan U Gutterman
Identification of molecular variants of p210bcr-abl in chronic myelogenous leukemia.
Blood 1987;70(1):233-6.
1987: Razelle Kurzrock; M Shtalrid; P Romero; W S Kloetzer; M Talpas; J M Trujillo; M Blick; Miloslav Beran; Jordan U Gutterman
A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia.
Nature 1987;325(6105):631-5.
1987: Hagop M Kantarjian; Moshe Talpaz; Razelle Kurzrock; M J Keating; K B McCredie; Jordan U Gutterman; Emil J Freireich
Intensive combination chemotherapy and interferons in the management of chronic myelogenous leukemia.
Acta haematologica 1987;78 Suppl 1():70-4.